Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis.

<h4>Background</h4>To assess the cardiovascular (CV) risk associated with the use of incretin-based therapy in adult patients with type 2 diabetes mellitus (T2DM) primary prevention group with low CV risks.<h4>Methods</h4>The clinical studies on incretin-based therapy publish...

Full description

Saved in:
Bibliographic Details
Main Authors: Je-Yon Kim, Seungwon Yang, Jangik I Lee, Min Jung Chang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0153502
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849710814556061696
author Je-Yon Kim
Seungwon Yang
Jangik I Lee
Min Jung Chang
author_facet Je-Yon Kim
Seungwon Yang
Jangik I Lee
Min Jung Chang
author_sort Je-Yon Kim
collection DOAJ
description <h4>Background</h4>To assess the cardiovascular (CV) risk associated with the use of incretin-based therapy in adult patients with type 2 diabetes mellitus (T2DM) primary prevention group with low CV risks.<h4>Methods</h4>The clinical studies on incretin-based therapy published in medical journals until August 2014 were comprehensively searched using MEDLINE, EMBASE and CENTRAL with no language restriction. The studies were systemically reviewed and evaluated for CV risks using a meta-analysis approach and where they meet the following criteria: clinical trial, incidence of predefined CV disease, T2DM with no comorbidities, age > 18 years old, duration of at least 12 weeks, incretin-based therapy compared with other antihyperglycaemic agents or placebo. Statistical analyses were performed using a Mantel-Haenszel (M-H) test. The odds ratios (OR) and their 95% confidence interval (CI) were estimated and displayed for comparison.<h4>Results</h4>A total of 75 studies comprising 45,648 patients with T2DM were selected. The pooled estimate demonstrated no significance in decreased CV risk with incretin-based therapy versus control (M-H OR, 0.90; 95% CI, 0.81-1.00).<h4>Conclusions</h4>This meta-analysis suggests that incretin-based therapy show no significant protective effect on CV events in T2DM primary prevention group with low CV risks. Prospective randomized controlled trials are required to confirm the results of this analysis.
format Article
id doaj-art-4edf2b4f62794bdba1ba8e81518c84db
institution DOAJ
issn 1932-6203
language English
publishDate 2016-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-4edf2b4f62794bdba1ba8e81518c84db2025-08-20T03:14:47ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01114e015350210.1371/journal.pone.0153502Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis.Je-Yon KimSeungwon YangJangik I LeeMin Jung Chang<h4>Background</h4>To assess the cardiovascular (CV) risk associated with the use of incretin-based therapy in adult patients with type 2 diabetes mellitus (T2DM) primary prevention group with low CV risks.<h4>Methods</h4>The clinical studies on incretin-based therapy published in medical journals until August 2014 were comprehensively searched using MEDLINE, EMBASE and CENTRAL with no language restriction. The studies were systemically reviewed and evaluated for CV risks using a meta-analysis approach and where they meet the following criteria: clinical trial, incidence of predefined CV disease, T2DM with no comorbidities, age > 18 years old, duration of at least 12 weeks, incretin-based therapy compared with other antihyperglycaemic agents or placebo. Statistical analyses were performed using a Mantel-Haenszel (M-H) test. The odds ratios (OR) and their 95% confidence interval (CI) were estimated and displayed for comparison.<h4>Results</h4>A total of 75 studies comprising 45,648 patients with T2DM were selected. The pooled estimate demonstrated no significance in decreased CV risk with incretin-based therapy versus control (M-H OR, 0.90; 95% CI, 0.81-1.00).<h4>Conclusions</h4>This meta-analysis suggests that incretin-based therapy show no significant protective effect on CV events in T2DM primary prevention group with low CV risks. Prospective randomized controlled trials are required to confirm the results of this analysis.https://doi.org/10.1371/journal.pone.0153502
spellingShingle Je-Yon Kim
Seungwon Yang
Jangik I Lee
Min Jung Chang
Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis.
PLoS ONE
title Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis.
title_full Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis.
title_fullStr Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis.
title_full_unstemmed Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis.
title_short Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis.
title_sort cardiovascular effect of incretin based therapy in patients with type 2 diabetes mellitus systematic review and meta analysis
url https://doi.org/10.1371/journal.pone.0153502
work_keys_str_mv AT jeyonkim cardiovasculareffectofincretinbasedtherapyinpatientswithtype2diabetesmellitussystematicreviewandmetaanalysis
AT seungwonyang cardiovasculareffectofincretinbasedtherapyinpatientswithtype2diabetesmellitussystematicreviewandmetaanalysis
AT jangikilee cardiovasculareffectofincretinbasedtherapyinpatientswithtype2diabetesmellitussystematicreviewandmetaanalysis
AT minjungchang cardiovasculareffectofincretinbasedtherapyinpatientswithtype2diabetesmellitussystematicreviewandmetaanalysis